Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Afatinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ACCEPT
- 02 Feb 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 02 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.